A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Status:
Terminated
Trial end date:
2020-10-13
Target enrollment:
Participant gender:
Summary
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder)
carcinoma with at least 2 measurable sites of disease. All eligible patients will be randomly
assigned to immunotherapy(nivolumab/atezolizumab/pembrolizumab) versus immunotherapy
(nivolumab/atezolizumab/pembrolizumab) plus radiotherapy, 10 Gy x3 (conformally or by
intensity modulation radiation therapy/Image-guided radiation therapy (IMRT/IGRT) to
maximally spare normal tissue), to one of their measurable lesions.